Clearer commercial thinking for portfolio choices.
Portfolio decisions shape where a company places its bets. Which indications move first. How an asset is positioned. Where launch investment goes. How risk is spread across markets, timelines and competitive scenarios.
These choices are rarely straightforward. They sit at the intersection of commercial opportunity, competitive change, pricing and access, launch timing, and the practical trade-offs that leadership teams have to make under uncertainty. DSX helps bring those factors into clearer view so that portfolio choices are based on a more realistic understanding of value and risk.
Portfolio strategy is not just about ranking opportunities. It is about understanding what will really drive value over time, where assumptions are too optimistic, and how different choices reshape the portfolio as a whole. A strong portfolio view needs to reflect how markets evolve, how access differs across regions, how timing affects opportunity, and how individual asset choices interact with each other.
The framework
A useful portfolio strategy process usually needs to answer five questions clearly.
Which opportunities matter most?
The starting point is to understand where the strongest commercial opportunities actually sit. That means looking beyond headline market size to consider treatable populations, differentiation, evidence requirements, competitive density, pricing and access, and time to market. The aim is to identify which indications or assets deserve priority and which are less attractive once the commercial realities are made explicit.
How will the competitive picture change?
Portfolio choices cannot be based on today's market alone. Pipeline entrants, mechanism competition, label expansion and shifts in treatment pathways can materially change the outlook over time. DSX helps leadership teams assess how those changes are likely to affect relative opportunity, positioning and long-term portfolio value.
Where and when should assets be launched?
Launch sequencing has a direct effect on portfolio value. The order in which markets are approached, the timing of entry, and the interaction with pricing and reimbursement pathways can all alter the shape of the opportunity. Portfolio strategy therefore needs to reflect regulatory timing, HTA processes, pricing corridors, competitive entry and operational readiness across geographies, rather than assuming one market path fits all.
Where is portfolio risk building up?
Risk is often spread unevenly across a portfolio. Several assets may depend on similar assumptions around competition, access or timing. A portfolio can appear balanced on paper while still carrying concentrated exposure in a few critical areas. DSX helps map where those pressures sit so leadership teams can see how commercial risk is accumulating across assets, indications and markets.
How does the picture change under different scenarios?
A single portfolio plan rarely survives intact once market conditions shift. Scenario work helps test how the portfolio changes if competitor timing moves, pricing comes under pressure, access is slower than expected, or regulatory timelines slip. That provides a stronger basis for discussion and helps teams prepare for a range of plausible futures rather than relying on one central case.
How stronger portfolio choices are made
DSX typically supports portfolio strategy work in situations such as indication prioritisation, launch sequencing, competitive positioning, early-stage commercial opportunity assessment, portfolio review ahead of leadership discussions, and commercial input into BD&L decisions. The output may include prioritisation frameworks, competitive landscape analysis, scenario-based portfolio modelling, launch planning views and clear materials to support leadership discussions.
An international commercial perspective is also central to this work. Portfolio choices are often weakened when they rely too heavily on a single-market view. Experience across US, EU and UK pricing and access environments, HTA-driven systems, rare disease markets and launch sequencing across regions helps ensure that the portfolio strategy reflects how opportunity really plays out across markets.
At its best, portfolio strategy gives leadership teams more than a list of priorities. It provides a clearer view of where value is most likely to come from, where the assumptions are weakest, and how to make more confident commercial choices across the portfolio.